Retreatment with lenalidomide is an effective option in heavily
pretreated refractory multiple myeloma patients

J 2018

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ et. al.

Basic information

Original name

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

Authors

ŠTORK, Martin (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk ADAM (203 Czech Republic), Marta KREJČÍ (203 Czech Republic), Viera SANDECKÁ (703 Slovakia), Zdeněk KRÁL (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Roberta VELICHOVÁ (703 Slovakia, belonging to the institution) and Luděk POUR (203 Czech Republic)

Edition

Neoplasma, Bratislava, Slovenská akademie vied, 2018, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.771

RIV identification code

RIV/00216224:14110/18:00106916

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4149/neo_2018_170519N363

UT WoS

000440172400012

Keywords in English

multiple myeloma; lenalidomide; retreatment

Abstract

V originále

The combination of lenalidomide and dexamethasone is the current gold standard for treatment of relapsed multiple myeloma. This study analyzes the efficiency of repeated lenalidomide treatment in patients with relapsed and refractory multiple myeloma. A total of 41 patients were prospectively evaluated at the University Hospital Brno. Lenalidomide was administered at standard dosing and in combination with corticosteroids and/or chemotherapy. The maximum cumulative dose of lenalidomide was limited to 4,200 mg because of Czech health insurance rules. Before the second lenalidomide treatment, all patients were refractory to the last treatment; previously, 95% of patients had bortezomib treatment, 48% had autologous transplantation and the median number of prior therapy lines was three. A partial 14.2% or better response was achieved with the second lenalidomide treatment. The median progression-free survival was 4.8 months, and median overall survival was 11.9 months. Unfortunately, predicting risk factors in lenalidomide retreatment proved unsuccessful. Although our treatment results were significantly affected by limited Czech health care system coverage for lenalidomide, we established that its repeated treatment is an effective therapeutic alternative for heavily pretreated patients with relapsed and refractory multiple myeloma.

Links

MUNI/A/1106/2016, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)

Investor: Masaryk University, Category A

NV15-29508A, research and development project

Name: Cirkulující nukleové kyseliny jako markery progrese mnohočetného myelomu

Citovat

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Zdeněk KRÁL, Lucie BROŽOVÁ, Roberta VELICHOVÁ and Luděk POUR. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients (Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.). Neoplasma. Bratislava: Slovenská akademie vied, 2018, vol. 65, No 4, p. 585-591. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2018_170519N363.

@article{1404546,
   author = {Štork, Martin and Ševčíková, Sabina and Adam, Zdeněk and Krejčí, Marta and Sandecká, Viera and Král, Zdeněk and Brožová, Lucie and Velichová, Roberta and Pour, Luděk},
   article_location = {Bratislava},
   article_number = {4},
   doi = {http://dx.doi.org/10.4149/neo_2018_170519N363},
   keywords = {multiple myeloma; lenalidomide; retreatment},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients},
   volume = {65},
   year = {2018}
}

TY  - JOUR
ID  - 1404546
AU  - Štork, Martin - Ševčíková, Sabina - Adam, Zdeněk - Krejčí, Marta - Sandecká, Viera - Král, Zdeněk - Brožová, Lucie - Velichová, Roberta - Pour, Luděk
PY  - 2018
TI  - Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients
JF  - Neoplasma
VL  - 65
IS  - 4
SP  - 585-591
EP  - 585-591
PB  - Slovenská akademie vied
SN  - 00282685
KW  - multiple myeloma
KW  - lenalidomide
KW  - retreatment
N2  - The combination of lenalidomide and dexamethasone is the current gold standard for treatment of relapsed multiple myeloma. This study analyzes the efficiency of repeated lenalidomide treatment in patients with relapsed and refractory multiple myeloma. A total of 41 patients were prospectively evaluated at the University Hospital Brno. Lenalidomide was administered at standard dosing and in combination with corticosteroids and/or chemotherapy. The maximum cumulative dose of lenalidomide was limited to 4,200 mg because of Czech health insurance rules. Before the second lenalidomide treatment, all patients were refractory to the last treatment; previously, 95% of patients had bortezomib treatment, 48% had autologous transplantation and the median number of prior therapy lines was three. A partial 14.2% or better response was achieved with the second lenalidomide treatment. The median progression-free survival was 4.8 months, and median overall survival was 11.9 months. Unfortunately, predicting risk factors in lenalidomide retreatment proved unsuccessful. Although our treatment results were significantly affected by limited Czech health care system coverage for lenalidomide, we established that its repeated treatment is an effective therapeutic alternative for heavily pretreated patients with relapsed and refractory multiple myeloma.
ER  -

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Zdeněk KRÁL, Lucie BROŽOVÁ, Roberta VELICHOVÁ and Luděk POUR. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients (Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.). \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2018, vol.~65, No~4, p.~585-591. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2018\_{}170519N363.

Detailed Information on Publication Record